Ottaviano, M., Mallardo, D., Simeone, E., Vecchio, M. D., Pigozzo, J., Ridolfi, L., Ferraresi, V., Mandala, M., Troiani, T., Curigliano, G., Paone, M., Caraco, C., Giannarelli, D., Merchant, N., Yavari, A., Blank, C. U., Ascierto, P. A. (2026). A multicenter, randomized phase Ib trial to evaluate neoadjuvant immunotherapy combination of nivolumab alone or plus ipilimumab with the IL-2 superkine MDNA11 alone or with tocilizumab in patients with high-risk, surgically resectable melanoma: The NEO-CYT trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps9612